{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:05:50Z","timestamp":1794027950489,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41375-026-02903-8","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:22:33Z","timestamp":1776252153000},"page":"1009-1017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Haploidentical versus matched unrelated donor transplantation with post-transplant cyclophosphamide: a platform-dependent machine learning analysis of donor age"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-544X","authenticated-orcid":false,"given":"Rohtesh S.","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7736-2056","authenticated-orcid":false,"given":"Christopher G.","family":"Kanakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Nawas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-6436","authenticated-orcid":false,"given":"Aleksandr","family":"Lazaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-3618","authenticated-orcid":false,"given":"Jennifer A.","family":"Kanakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5054-9419","authenticated-orcid":false,"given":"Shernan","family":"Holtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Al-Juhaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Cataquiz","family":"Rimando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1114-9508","authenticated-orcid":false,"given":"Anurag","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-9466","authenticated-orcid":false,"given":"Jennifer","family":"Saultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2813-6781","authenticated-orcid":false,"given":"Shannon R.","family":"Mccurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-2159","authenticated-orcid":false,"given":"Filippo","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2903_CR1","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bolanos-Meade","year":"2023","unstructured":"Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u20132348.","journal-title":"N Engl J Med"},{"key":"2903_CR2","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.24.00184","volume":"42","author":"BC Shaffer","year":"2024","unstructured":"Shaffer BC, Gooptu M, DeFor TE, Maiers M, Bolanos-Meade J, Abboud R, et al. Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors. J Clin Oncol. 2024;42:3277\u20133286.","journal-title":"J Clin Oncol"},{"key":"2903_CR3","first-page":"917 e1","volume":"30","author":"R Cusatis","year":"2024","unstructured":"Cusatis R, Litovich C, Feng Z, Allbee-Johnson M, Kapfhammer M, Mattila D, et al. Current trends and outcomes in cellular therapy activity in the United States, including prospective patient-reported outcomes data collection in the Center for International Blood and Marrow Transplant Research Registry. Transpl Cell Ther. 2024;30:917 e1\u2013917 e12.","journal-title":"Transpl Cell Ther"},{"key":"2903_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood.2021011281","volume":"138","author":"M Gooptu","year":"2021","unstructured":"Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021;138:273\u2013282.","journal-title":"Blood"},{"key":"2903_CR5","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1182\/bloodadvances.2022007741","volume":"6","author":"A Ambinder","year":"2022","unstructured":"Ambinder A, Jain T, Tsai HL, Horowitz MM, Jones RJ, Varadhan R. HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age. Blood Adv. 2022;6:4335\u20134346.","journal-title":"Blood Adv"},{"key":"2903_CR6","first-page":"395 e1","volume":"28","author":"RS Mehta","year":"2022","unstructured":"Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, et al. Haploidentical versus matched unrelated versus matched sibling donor hematopoietic cell transplantation with post-transplantation cyclophosphamide. Transpl Cell Ther. 2022;28:395 e1\u2013395 e11.","journal-title":"Transpl Cell Ther"},{"key":"2903_CR7","first-page":"377 e1","volume":"29","author":"RS Mehta","year":"2023","unstructured":"Mehta RS, Ramdial J, Marin D, Alousi A, Kanakry CG, Champlin RE, et al. Impact of donor age in haploidentical-post-transplantation cyclophosphamide versus matched unrelated donor post-transplantation cyclophosphamide hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Transpl Cell Ther. 2023;29:377 e1\u2013377 e7.","journal-title":"Transpl Cell Ther"},{"key":"2903_CR8","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/bloodadvances.2024014858","volume":"9","author":"K Nath","year":"2025","unstructured":"Nath K, Zhang MJ, Bye M, Abid MB, Benjamin C, Betts B, et al. Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis. Blood Adv. 2025;9:3469\u20133478.","journal-title":"Blood Adv"},{"key":"2903_CR9","doi-asserted-by":"crossref","unstructured":"Devine S, Astha V, Kuxhausen M, Bupp C, Stefanski H, Shaw B, et al. Os5-02: Do patient outcomes differ by donor type if post-transplant cyclophosphamide is used for GVHD prophylaxis? A cibmtr retrospective analysis. The 51stAnnual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Session (O008-O166). Bone Marrow Transplant. 2025;60:19\u2013182.","DOI":"10.1038\/s41409-025-02650-x"},{"key":"2903_CR10","doi-asserted-by":"publisher","unstructured":"Mehta RS, Schmidt G, Williams K, Patel SA, Schetelig J, Savani B, et al. Choosing between HLA-mismatched unrelated and haploidentical donors: donor age considerations. Transplant Cell Ther. 2025. https:\/\/doi.org\/10.1016\/j.jtct.2025.05.019.","DOI":"10.1016\/j.jtct.2025.05.019"},{"key":"2903_CR11","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/s41409-024-02400-5","volume":"59","author":"A Nagler","year":"2024","unstructured":"Nagler A, Labopin M, Swoboda R, Blaise D, Angelucci E, Vydra J, et al. Young (<35 years) haploidentical versus old (>\/=35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2024;59:1552\u20131562.","journal-title":"Bone Marrow Transpl"},{"key":"2903_CR12","doi-asserted-by":"publisher","unstructured":"Aljawai YM, Ramdial JL, Rondon G, Smallbone P, Kebriaei P, Popat UR, et al. Outcomes of haploidentical vs mismatched unrelated donor HCT with post-transplant cyclophosphamide prophylaxis. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2025016236.","DOI":"10.1182\/bloodadvances.2025016236"},{"key":"2903_CR13","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","volume":"5","author":"AE DeZern","year":"2021","unstructured":"DeZern AE, Franklin C, Tsai HL, Imus PH, Cooke KR, Varadhan R, et al. Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv Mar. 2021;5:1360\u20131368.","journal-title":"Blood Adv Mar"},{"key":"2903_CR14","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/bloodadvances.2023012133","volume":"8","author":"J Sanz","year":"2024","unstructured":"Sanz J, Labopin M, Blaise D, Raiola AM, Busca A, Vydra J, et al. Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT. Blood Adv. 2024;8:2332\u20132341.","journal-title":"Blood Adv"},{"key":"2903_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ajh.27126","volume":"99","author":"RM Saliba","year":"2024","unstructured":"Saliba RM, Kanakry CG, Gadalla S, Kebriaei P, Rezvani K, Champlin RE, et al. Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. Am J Hematol. 2024;99:38\u201347.","journal-title":"Am J Hematol"},{"key":"2903_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/bloodadvances.2017014829","volume":"2","author":"SR McCurdy","year":"2018","unstructured":"McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, et al. Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Adv. 2018;2:299\u2013307.","journal-title":"Blood Adv"},{"key":"2903_CR17","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood.2021013443","volume":"139","author":"EJ Fuchs","year":"2022","unstructured":"Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MM, Modi D, et al. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood. 2022;139:1452\u20131468.","journal-title":"Blood"},{"key":"2903_CR18","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1182\/bloodadvances.2024012669","volume":"8","author":"RS Mehta","year":"2024","unstructured":"Mehta RS, Petersdorf EW, Spellman SR, Lee SJ. Combined effect of unrelated donor age and HLA peptide-binding motif match status on HCT outcomes. Blood Adv. 2024;8:2235\u20132242.","journal-title":"Blood Adv"},{"key":"2903_CR19","first-page":"909 e1","volume":"30","author":"RS Mehta","year":"2024","unstructured":"Mehta RS, Petersdorf EW, Wang T, Lee SJ. Haploidentical versus mismatched unrelated donor hematopoietic cell transplantation: HLA factors and donor age considerations. Transpl Cell Ther. 2024;30:909 e1\u2013909 e11.","journal-title":"Transpl Cell Ther"},{"key":"2903_CR20","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/ajh.27648","volume":"100","author":"RS Mehta","year":"2025","unstructured":"Mehta RS, Sparapani R, Wang T, Spellman S, Lee SJ, Petersdorf EW. Donor age matters for haploidentical HCT patients even after adjusting for HLA factors: a machine-learning approach. Am J Hematol. 2025;100:937\u2013940.","journal-title":"Am J Hematol"},{"key":"2903_CR21","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","volume":"127","author":"C Kollman","year":"2016","unstructured":"Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016;127:260\u20137.","journal-title":"Blood"},{"key":"2903_CR22","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bbmt.2018.02.006","volume":"24","author":"BE Shaw","year":"2018","unstructured":"Shaw BE, Logan BR, Spellman SR, Marsh SGE, Robinson J, Pidala J, et al. Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most. Biol Blood Marrow Transpl. 2018;24:1049\u20131056.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2903_CR23","first-page":"494","volume":"5","author":"BR Logan","year":"2021","unstructured":"Logan BR, Maiers MJ, Sparapani RA, Laud PW, Spellman SR, McCulloch RE, et al. Optimal donor selection for hematopoietic cell transplantation using Bayesian machine learning. JCO Clin Cancer Inf. 2021;5:494\u2013507.","journal-title":"JCO Clin Cancer Inf"},{"key":"2903_CR24","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1182\/bloodadvances.2024013756","volume":"8","author":"SR Spellman","year":"2024","unstructured":"Spellman SR, Sparapani R, Maiers M, Shaw BE, Laud P, Bupp C, et al. Novel machine learning technique further clarifies unrelated donor selection to optimize transplantation outcomes. Blood Adv. 2024;8:6082\u20136087.","journal-title":"Blood Adv"},{"key":"2903_CR25","doi-asserted-by":"crossref","unstructured":"Mehta RS, Aljawai YM, Kebriaei P, Olson A, Oran B, Rondon G, et al. The impact of isolated HLA-DQB1 mismatch and donor age in unrelated donor hematopoietic cell transplantation with post-transplant cyclophosphamide. Transplant Cell Ther. 2025;31:920.e1\u2013920.e14.","DOI":"10.1016\/j.jtct.2025.08.011"},{"key":"2903_CR26","first-page":"672 e1","volume":"31","author":"RS Mehta","year":"2025","unstructured":"Mehta RS, Aljawai YM, Al-Juhaishi T, Saultz J, Milano F, Kanakry JA, et al. Role of donor cytomegalovirus serostatus in cytomegalovirus-seronegative recipients of unrelated donor hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis. Transpl Cell Ther. 2025;31:672 e1\u2013672 e9.","journal-title":"Transpl Cell Ther"},{"key":"2903_CR27","doi-asserted-by":"crossref","unstructured":"Mehta RS, Sparapani RA, Kanakry CG, McCurdy SR, Saultz J, Lazaryan A, et al. Unrelated donor age and recipient outcomes after posttransplant cyclophosphamide vs conventional prophylaxis. JAMA Oncol. 2025;12:28\u201337.","DOI":"10.1001\/jamaoncol.2025.4551"},{"key":"2903_CR28","unstructured":"CIBMTR. https:\/\/cibmtr.org\/CIBMTR\/Resources\/Publicly-Available-Datasets#, accessed 9\/6\/ (2023)."},{"key":"2903_CR29","first-page":"680","volume":"31","author":"RS Mehta","year":"2025","unstructured":"Mehta RS, Schmidt G, Williams K, Patel SA, Schetelig J, Savani B, et al. Choosing between HLA-mismatched unrelated and haploidentical donors: donor age considerations. Transpl Cell Ther. 2025;31:680\u201392.","journal-title":"Transpl Cell Ther"},{"key":"2903_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41392-022-01251-0","volume":"7","author":"J Guo","year":"2022","unstructured":"Guo J, Huang X, Dou L, Yan M, Shen T, Tang W, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduct Target Ther. 2022;7:391.","journal-title":"Signal Transduct Target Ther"},{"key":"2903_CR31","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1038\/s41591-024-03164-7","volume":"30","author":"MA Argentieri","year":"2024","unstructured":"Argentieri MA, Xiao S, Bennett D, Winchester L, Nevado-Holgado AJ, Ghose U, et al. Proteomic aging clock predicts mortality and risk of common age-related diseases in diverse populations. Nat Med Sep. 2024;30:2450\u20132460.","journal-title":"Nat Med Sep"},{"key":"2903_CR32","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s43587-024-00692-2","volume":"4","author":"X Shen","year":"2024","unstructured":"Shen X, Wang C, Zhou X, Zhou W, Hornburg D, Wu S, et al. Nonlinear dynamics of multi-omics profiles during human aging. Nat Aging. 2024;4:1619\u20131634.","journal-title":"Nat Aging"},{"key":"2903_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1400610","volume":"15","author":"JC Jaime-Perez","year":"2024","unstructured":"Jaime-Perez JC, Valdespino-Valdes J, Gomez-De Leon A, Barragan-Longoria RV, Dominguez-Villanueva A, Cantu-Rodriguez OG, et al. A comparison of haploidentical versus HLA-identical sibling outpatient hematopoietic cell transplantation using reduced intensity conditioning in patients with acute leukemia. Front Immunol. 2024;15:1400610.","journal-title":"Front Immunol"},{"key":"2903_CR34","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1080\/10428194.2024.2344060","volume":"65","author":"PA von dem Borne","year":"2024","unstructured":"von dem Borne PA, Kemps-Mols BM, de Wreede LC, van Beek AA, Snijders TJF, van Lammeren D, et al. The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide. Leuk Lymphoma. 2024;65:1270\u20131280.","journal-title":"Leuk Lymphoma"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02903-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02903-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02903-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:26:34Z","timestamp":1778048794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02903-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2903"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02903-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RSM: consultancy for OrcaBio and expert opinion for Lumanity. AL: Sanofi: consultancy\/honoraria\/scientific advisory board, Incyte: consultancy\/honoraria, Pierre Fabre: consultancy\/honoraria. Other authors report no relevant conflicts of interest. SH: VITRAC Therapeutics (research funding), Incyte (research funding), CSL Behring (clinical trial adjudication), Sanofi (non-branded educational programming), MaaT Pharma (advisory board), Ossium (advisory board). TA-J: KITE Pharma and Stemline Therapeutics (advisory board).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}